CERo Therapeutics Holdings, Inc. (CERO) shareholders
Close on Oct 19, 2026Market cap $253.05KP/E –Yield 172833.33%
Ownership
Institutional holdings as of Dec 31, 2025, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| SMS Revocable Trust | 21,067,956 | – | 13G (passive) amendment | Sep 24, 2024 |
| Lawrence Corey | 8,529,316 | 5.70% | 13G (passive) | Dec 10, 2024 |
| Jurgen van de Vyver Joint filing with Phoenix Biotech Sponsor, LLC (6.70%) | 1,015,000 | 6.80% | 13D (active) amendment | Feb 14, 2024 |
| Steven Boyd Joint filing with Armistice Capital, LLC (9.99%) | 584,548 | 9.99% | 13G (passive) | Mar 31, 2025 |
| Brian G. Atwood Joint filing with Atwood-Edminster Trust dtd 4-2-2000 (9.50%), Lynne H. Edminster (9.50%) | 511,800 | 9.90% | 13D (active) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Sep 30, 2025
| Holder | Shares | % of CERO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Parallel Advisors, LLC | 121,000 | – | $615.89K | −99,000 | 0.01% |
| ARCH Venture Management, LLC | 22,389 | – | $113.96K | – | 0.02% |
| Susquehanna International Group, Llp | 10,244 | – | $52.14K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 1,299 | – | $6.61K | +615 | 0.00% |
| FNY Investment Advisers, LLC | 1,050 | – | $5.00K | – | 0.00% |
| Citigroup Inc | 968 | – | $4.93K | New | 0.00% |
| SBI Securities Co., Ltd. | 18 | – | $92 | – | 0.00% |
| UBS Group AG | 6 | – | $30 | −2,619 | 0.00% |
| Bank Of America Corp /De/ | 3 | – | $15 | +1 | 0.00% |
| Jones Financial Companies Lllp | 3 | – | $16 | – | 0.00% |
| Royal Bank of Canada | 1 | – | $0 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q4 2025 | 0 | 0M | 0 / 0 | 0 / 11 | 0M | 0M |
| Q3 2025 | 11 | 0M | 3 / 2 | 2 / 0 | 0M | 0M |
| Q2 2025 | 8 | 0M | 8 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Christopher B. Ehrlich | Chairman and CEO, Director | 11,091,654 | Jan 9, 2026 |
| Kristen Pierce | Chief Development Officer | – | Jan 9, 2026 |
| Andrew Albert Kucharchuk | Chief Financial Officer | – | Jan 9, 2026 |
| Eric Francois | Director | – | Apr 21, 2026 |
| Shami Patel | Director | 1,120,254 | Jan 9, 2026 |
| Lindsey Rolfe | Director | – | Jan 9, 2026 |
| Michael Byrnes | Director | – | Jan 9, 2026 |
| Kathleen Laporte | Director | 989,325 | Jan 9, 2026 |
| Brian G. Atwood | Director | 491,784 | Jan 9, 2026 |
| Mitchell William Kossar | 10% owner | 18,962,419 | Dec 13, 2024 |
| YK Bioventures Opportunities GP I, LLC | 10% owner | 13,005,169 | Dec 13, 2024 |
| YK Bioventures Opportunities Fund I, L.P. | 10% owner | – | Dec 13, 2024 |
| Gary Kahing Yeung | 10% owner | 25,870,783 | Dec 13, 2024 |
| Stuart M. Sloan | 10% owner | 21,067,956 | Nov 20, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brian G. Atwood Director | Mar 31, 2025 | Option exercise | +294,460 | – | – | 490,534 |
| YK Bioventures Opportunities GP I, LLC 10% owner | Dec 13, 2024 | Sale | −2,998,908 | $0.06 | $179.93K | 13,005,169 |
| YK Bioventures Opportunities GP I, LLC 10% owner | Dec 12, 2024 | Sale | −1,614,541 | $0.07 | $113.02K | 16,004,077 |
| YK Bioventures Opportunities GP I, LLC 10% owner | Dec 11, 2024 | Sale | −1,343,801 | $0.08 | $107.50K | 17,618,618 |
| Mitchell William Kossar 10% owner | Dec 10, 2024 | Sale | −1,570,947 | $0.09 | $141.39K | 18,962,419 |
| Mitchell William Kossar 10% owner | Dec 9, 2024 | Sale | −850,543 | $0.11 | $93.56K | 20,533,366 |
| Mitchell William Kossar 10% owner | Dec 6, 2024 | Sale | −1,236,874 | $0.12 | $148.42K | 21,383,909 |
| Mitchell William Kossar 10% owner | Oct 10, 2024 | Sale | −3,250,000 | $0.10 | $325.00K | 22,620,783 |
| Stuart M. Sloan 10% owner | Sep 25, 2024 | Sale | −532,486 | $0.10 | $53.25K | 21,067,956 |
| Brian G. Atwood Director | Sep 25, 2024 | Option exercise | +19,358,578 | – | – | 19,607,313 |
| Kathleen Laporte Director | Sep 25, 2024 | Option exercise | +965,997 | – | – | 965,997 |
| Christopher B. Ehrlich Interim Chairman and CEO, Director | Sep 25, 2024 | Option exercise | +5,312,983 | – | – | 5,791,808 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +148,208 | – | – | 248,735 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +100,527 | – | – | 100,527 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +148,208 | – | – | 248,735 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +100,527 | – | – | 100,527 |
| Caroline M. Loewy Director | Feb 14, 2024 | Other | +5,828 | – | – | 5,828 |
| Douglas Carl Fisher President | Feb 14, 2024 | Other | +43,300 | – | – | 43,300 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +148,208 | – | – | 248,735 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +100,527 | – | – | 100,527 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +125,000 | – | – | 125,000 |
| Kathleen Laporte Director | Feb 14, 2024 | Other | +5,828 | – | – | 5,828 |
| Daniel E. Geffken Chief Financial Officer | Feb 14, 2024 | Other | +10,002 | – | – | 10,002 |
| Christopher B. Ehrlich Director | Feb 14, 2024 | Other | +3,600 | – | – | 3,600 |
| Christopher B. Ehrlich Director | Feb 14, 2024 | Other | +478,825 | – | – | 478,825 |
| Christopher B. Ehrlich Director | Feb 14, 2024 | Other | −4,171,246 | – | – | 1,000,000 |
| Christopher B. Ehrlich Director | Feb 14, 2024 | Other | −1,125,000 | – | – | 4,171,246 |
| Phoenix Biotech Sponsor, Llc 10% owner | Feb 14, 2024 | Other | −4,171,246 | – | – | 1,000,000 |
| Phoenix Biotech Sponsor, Llc 10% owner | Feb 14, 2024 | Other | −1,125,000 | – | – | 4,171,246 |
| Barbara Kosacz Director | Feb 14, 2024 | Other | +5,828 | – | – | 5,828 |
| Douglas Carl Fisher President | Oct 8, 2021 | Other | +10,000 | – | – | 10,000 |
| Christopher B. Ehrlich CEO and Secretary, Director, 10% owner | Oct 8, 2021 | Other | +36,733 | $10.00 | $367.33K | 699,996 |
| Phoenix Biotech Sponsor, Llc 10% owner | Oct 8, 2021 | Other | +36,733 | $10.00 | $367.33K | 699,996 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CERo Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 480,300 shares on Aug 27, 2026 over the last 90 days.
See a number that looks wrong?